drugset / Trial / NCT00932646

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646

Phase 3 Completed 100 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Timeline

Start
2009-06
Primary completion
2010-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 12 ug Inhaled
Subject Olodaterol Small molecule 5 ug Inhaled
Subject Olodaterol Small molecule 10 ug Inhaled